Literature DB >> 19881519

Liver transplantation after radioembolization in a patient with unresectable HCC.

Laura E Moreno Luna1, Paul Y Kwo, Lewis R Roberts, Teresa A Mettler, Denise N Gansen, James C Andrews, Gregory A Wiseman, Vijay Laxmi Misra.   

Abstract

BACKGROUND: A 58-year-old white man who was being followed by his hepatologist for nonalcoholic steatohepatitis-related liver cirrhosis and portal hypertension and who had been found to have a biopsy-proven hepatocellular carcinoma (HCC) on routine screening, self-referred to our center for a second opinion on the management of his HCC. INVESTIGATIONS: Laboratory investigations, CT scan of the abdomen and chest, bone scan and technetium macroaggregated albumin scan. DIAGNOSIS: The patient had unresectable HCC. MANAGEMENT: The patient underwent two treatments with Yttrium-90 glass microspheres, which were performed as outpatient procedures 1 month and 3 months after diagnosis. He underwent orthotopic liver transplantation (OLT) 1 year after the initial diagnosis of HCC. The post-OLT immunoregimen included OKT3 plus rituximab and high-dose steroids. On discharge from hospital he was on immunosuppressive treatment with tacrolimus. He had de novo autoimmune hepatitis 6 months post-OLT, which was treated with a short course of low-dose steroids and addition of mycophenolate mofetil.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19881519      PMCID: PMC2904913          DOI: 10.1038/nrgastro.2009.165

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  18 in total

Review 1.  Prognostic prediction and treatment strategy in hepatocellular carcinoma.

Authors:  Jordi Bruix; Josep M Llovet
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

2.  The quandary over liver transplantation for hepatocellular carcinoma: the greater sin?

Authors:  John Fung; Wallis Marsh
Journal:  Liver Transpl       Date:  2002-09       Impact factor: 5.799

3.  Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria.

Authors:  Francis Y Yao; Linda Ferrell; Nathan M Bass; Peter Bacchetti; Nancy L Ascher; John P Roberts
Journal:  Liver Transpl       Date:  2002-09       Impact factor: 5.799

4.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

5.  A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators.

Authors: 
Journal:  Hepatology       Date:  1998-09       Impact factor: 17.425

6.  Yttrium-90 microspheres for the treatment of hepatocellular carcinoma.

Authors:  Jean Francois H Geschwind; Riad Salem; Brian I Carr; Michael C Soulen; Kenneth G Thurston; Kathleen A Goin; Mark Van Buskirk; Carol A Roberts; James E Goin
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

7.  Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients.

Authors:  Brian I Carr
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

8.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

Authors:  Sean F Altekruse; Katherine A McGlynn; Marsha E Reichman
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

9.  The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update.

Authors:  Hashem B El-Serag; Jessica A Davila; Nancy J Petersen; Katherine A McGlynn
Journal:  Ann Intern Med       Date:  2003-11-18       Impact factor: 25.391

10.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.

Authors:  V Mazzaferro; E Regalia; R Doci; S Andreola; A Pulvirenti; F Bozzetti; F Montalto; M Ammatuna; A Morabito; L Gennari
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 176.079

View more
  4 in total

1.  Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation.

Authors:  Giuseppe Maria Ettorre; Giovanni Battista Levi Sandri; Andrea Laurenzi; Marco Colasanti; Roberto Luca Meniconi; Raffaella Lionetti; Roberto Santoro; Pasquale Lepiane; Rosa Sciuto; Giuseppe Pizzi; Roberto Cianni; Rita Golfieri; Gianpiero D'Offizi; Adriano M Pellicelli; Mario Antonini; Giovanni Vennarecci
Journal:  World J Surg       Date:  2017-01       Impact factor: 3.352

Review 2.  Trans-arterial radio-embolization: a new chance for patients with hepatocellular cancer to access liver transplantation, a world review.

Authors:  Giovanni Battista Levi Sandri; Giuseppe Maria Ettorre; Valerio Giannelli; Marco Colasanti; Rosa Sciuto; Giuseppe Pizzi; Roberto Cianni; Gianpiero D'Offizi; Mario Antonini; Giovanni Vennarecci; Pierleone Lucatelli
Journal:  Transl Gastroenterol Hepatol       Date:  2017-11-27

Review 3.  Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review.

Authors:  Edward Wolfgang Lee; Lourdes Alanis; Sung-Ki Cho; Sammy Saab
Journal:  Korean J Radiol       Date:  2016-06-27       Impact factor: 3.500

Review 4.  Current Status of Malignant Tumors after Organ Transplantation.

Authors:  Bairu Shen; Zhuofei Cen; Minghua Tan; Changshan Song; Xuhui Wu; Jiaqing Wang; Minqian Huang
Journal:  Biomed Res Int       Date:  2022-02-18       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.